Recursion Pharmaceuticals (RXRX) Reports Q4 Results, Provides Business Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. USO
5. GNK
6. PLUR
7. MU
8. ARGX
9. AZN
10. SPCX

Go back to Recursion Pharmaceuticals (RXRX) Reports Q4 Results, Provides Business Updates

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results

March 23, 2022 7:55 AM EDT

Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40 novel potential medicinesExpanded our collaboration with Bayer to include the use of Recursion's OS to map and navigate biology and increased the number of potential programs in fibrosis to more than a dozenEnrolled the first patient in our Phase 2 clinical trial for CCMAdvanced our internal pipeline of potential oncology therapeutics, including programs related to CDK12, target alpha, STK11, MYC, and multiple new... More